P/E at 34.64 vs Industry's 33.60: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Premium Reflecting Sector Confidence

The P/E ratio of 34.64 for Sun Pharmaceutical Industries Ltd sits just above the industry average of 33.60, indicating that investors are willing to pay a small premium for the stock relative to its sector. This premium suggests a perception of stable earnings growth or quality relative to peers, though it is not excessive enough to imply overvaluation concerns. The company’s large-cap status, with a market capitalisation of ₹4,33,319.90 crores, further supports this valuation stance, as large-cap pharmaceutical firms often command steadier multiples due to their scale and diversified product portfolios.

However, the premium is modest, and the P/E remains within a range that reflects sector norms rather than a significant divergence. This valuation context is important for investors analysing whether the stock’s price adequately reflects its earnings prospects or if there is room for re-rating — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating? The four-parameter analysis factors in the valuation premium alongside other metrics.

Performance Across Timeframes: Divergent Momentum Signals

Examining Sun Pharmaceutical Industries Ltd’s returns reveals a complex performance profile. Over the past year, the stock has gained 7.15%, outperforming the Sensex which declined by 6.40% in the same period. This positive annual return underscores resilience amid broader market volatility and sector headwinds.

Yet, the shorter-term returns tell a more mixed story. The stock has declined by 3.94% over the last month, underperforming the Sensex’s 1.76% gain. Over the past week, it rose 1.49%, but this still lagged the Sensex’s 3.58% advance. The three-month return of 1.32% is roughly in line with the Sensex’s 1.40%, indicating a period of relative stability after recent fluctuations.

This divergence between medium-term weakness and longer-term strength suggests that recent market dynamics or company-specific factors have tempered momentum — is this a temporary setback or a sign of shifting fundamentals? The 5.02% year-to-date gain also contrasts with the Sensex’s 10.16% decline, reinforcing the stock’s relative outperformance in 2026 so far.

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is characterised by a nuanced moving average (MA) configuration. The stock price currently trades above its 5-day, 50-day, 100-day, and 200-day moving averages, signalling underlying strength and support at these levels. However, it remains below the 20-day moving average, indicating some short-term resistance and potential consolidation.

This pattern suggests a recent bounce within a broader trend, where short-term momentum is lagging despite longer-term averages holding firm. The stock’s two-day consecutive decline, with a cumulative fall of 0.3%, further highlights this short-term caution. The opening price of ₹1801.75 has remained steady during the trading session, reflecting a lack of decisive directional movement.

The 20-day MA acting as a ceiling may indicate a pause or minor correction in the rally, but the support from longer-term averages provides a technical floor — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The moving average configuration provides the clearest answer.

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings seasons. Out of 35 stocks that have declared results, 19 reported positive outcomes, 9 were flat, and 7 posted negative results. This distribution indicates a broadly stable sector environment with pockets of strength and weakness.

Sun Pharmaceutical Industries Ltd’s performance aligns with this sector backdrop, showing resilience amid a competitive and evolving industry landscape. The company’s ability to maintain a valuation premium and outperform the Sensex over one year reflects its relative strength within this mixed sector performance.

Rating Reassessment: Previously Hold, Now Updated

The rating for Sun Pharmaceutical Industries Ltd was previously Hold according to MarketsMOJO and was reassessed on 8 June 2026. While the current rating is not disclosed, the reassessment reflects a comprehensive review of valuation, performance, and technical factors. The company’s Mojo Score of 74.0 and large-cap market cap grade underpin its standing in the Pharmaceuticals & Biotechnology sector.

Given the valuation premium, mixed short-term momentum, and supportive moving average configuration, the updated rating likely incorporates these nuanced data points — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced Valuation and Mixed Momentum

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight premium to its sector, supported by solid one-year returns and a stable technical base. The mixed short-term performance and the stock’s position below the 20-day moving average suggest some caution in the near term, while longer-term moving averages provide a foundation for potential stability.

Sector results remain broadly positive, and the company’s reassessed rating reflects these multiple dimensions. Investors analysing this stock should weigh the valuation premium against the recent momentum shifts — what is the current rating for Sun Pharmaceutical Industries Ltd and how should it influence portfolio decisions?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →